Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

被引：0

作者：

Blauvelt, Andrew ^{[11
]}

Armstrong, April ^{[1
]}

Merola, Joseph F. ^{[2
]}

Strober, Bruce ^{[3
,4
,5
]}

de Cuyper, Dirk ^{[6
]}

Peterson, Luke ^{[7
]}

Davies, Owen ^{[8
]}

Stark, Jeffrey L. ^{[9
]}

Lebwohl, Mark ^{[10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Calif Los Angeles UCLA, Los Angeles, CA USA

[3] UT Southwestern Med Ctr, Div Rheumatol, Dept Dermatol, Dallas, TX USA

[4] UT Southwestern Med Ctr, Dept Med, Div Rheumatol, Dallas, TX USA

[5] Yale Univ, Dept Dermatol, New Haven, CT USA

[6] Cent Connecticut Dermatol Res, Cromwell, CT USA

[7] UCB Pharm, Brussels, Belgium

[8] UCB Pharm, Morrisville, NC USA

[9] UCB Pharm, Slough, England

[10] UCB Pharm, Smyrna, GA USA

[11] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 01期

关键词：

bimekizumab; clinical trial; depression; eC-SSRS; long-term; mental health; PHQ-9; plaque; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; BRODALUMAB; DEPRESSION; USTEKINUMAB; SUICIDALITY; EFFICACY; VALIDITY; ANXIETY;

D O I：

10.1016/j.jaad.2024.02.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Patients with psoriasis have increased risk of suicidal ideation and behavior (SIB) and depression. Bimekizumab, a biologic that inhibits interleukin (IL)-17A and IL-17F, received Food and Drug Administration approval in 2023 for moderate to severe plaque psoriasis, following 2021 European Medicines Agency approval. Objective: To report SIB and depression in patients with moderate to severe psoriasis treated in bimekizumab clinical trials. Methods: Mental health changes, including neuropsychiatric events, were actively monitored across 9 bimekizumab clinical trials in psoriasis phase 2/3 trials. The patient-reported electronic Columbia-Suicide Severity Rating Scale (measuring SIB) and Patient Health Questionnaire-9 (measuring depression) were administered, monitored by an independent Neuropsychiatric Adjudication Committee. Results: Throughout 7166 patient-years (PY) of bimekizumab exposure, the adjudicated SIB rate was 0.13/ 100PY; SIB ranges for the general psoriasis population and patients receiving anti-IL-17A/anti-IL-23

引用

页码：72 / 81

页数：10

共 50 条

[21] Bimekizumab safety and tolerability in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in five phase 3/3b clinical trials
Gordon, Kenneth B.
Gooderham, Melinda
Foley, Peter
Okubo, Yukari
Warren, Richard B.
Peterson, Luke
Madden, Cynthia
Szilagyi, Balint
Deherder, Delphine
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
[22] Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Blauvelt, Andrew
Papp, Kim A.
Lebwohl, Mark G.
Green, Lawrence J.
Hsu, Sylvia
Bhatt, Varsha
Rastogi, Shipra
Pillai, Radhakrishnan
Israel, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) : 372 - 374
[23] Clinical outcomes and quality of life in a cross-sectional study of patients with moderate-to-severe psoriasis treated with bimekizumab in routine clinical practice
Wicker, Gemma
Tredwell, Amanda
Topliffe, Joanne
Smith, Maureen
Vistenia, Jason
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I66 - I66
[24] Bimekizumab early treatment response translates into cumulative health-related quality of life benefits in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
Rubel, Diana
Gordon, Kenneth B.
Sebastian, Michael
Feldman, Steven R.
Eusebi, Paolo
Wixted, Krista
Madden, Cynthia
Gomez, Natalie Nunez
Ciaravino, Valerie
Radtke, Marc
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 19 - 20
[25] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
Armstrong, April W.
Lynde, Charles W.
McBride, Sandy R.
Stahle, Mona
Edson-Heredia, Emily
Zhu, Baojin
Amato, David
Nikai, Enkeleida
Yang, Fan Emily
Gordon, Kenneth B.
JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
[26] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Elewski, Boni
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
[27] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Eyerich, Kilian
Gottlieb, Alice B.
Piaserico, Stefano
Beissert, Stefan
Gooderham, Melinda
Kirby, Brian
Tilt, Nicola
Madden, Cynthia
Wiegratz, Susanne
de Cuyper, Dirk
Merola, Joseph F.
Elewski, Boni
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
[28] Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for palmoplantar psoriasis in patients with moderate to severe plaque psoriasis in phase 2 and phase 3 (ESTEEM) trials
Bissonnette, Robert
Cather, Jennifer
Rich, Phoebe
Menter, Alan
Ferrandiz, Carlos
Goodfield, Mark
Hu, ChiaChi
Day, Robert
Sebastian, Michael
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB234 - AB234
[29] Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Gordon, Kenneth B.
Sebastian, Michael
Feldman, Steven R.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
[30] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Armstrong, April W.
Augustin, Matthias
Beaumont, Jennifer L.
Pham, Tan P.
Hudgens, Stacie
Gordon, Kenneth B.
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Kisa, Renata M.
Banerjee, Subhashis
Papp, Kim A.
DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2235 - 2248

← 1 2 3 4 5 →